> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# QuidelOrtho Launches Restructuring Targeting Over $80 Million In 2027 Savings, As CEO Weighs 'Every Option' On Debt
- URL: https://www.bullished.co/quidelortho-launches-restructuring-targeting-over-80-million-in-2027-savings-as-ceo-weighs-48deb372/
- Published: 2026-11-03T23:02:06.000Z
- Updated: 2026-11-03T23:02:06.000Z
- Description: The diagnostics maker carries about $2.8 billion of net debt and loosened its leverage covenant to 5.5 times adjusted EBITDA.
- Author: Matteo Parrino
- Tags: Earnings, QDEL, Industry: Healthcare

[QuidelOrtho](https://www.bullished.co/tag/qdel/), which makes diagnostic tests and the instruments that run them, announced a cost-cutting and restructuring program it expects to save more than $80 million a year in 2027, Chief Financial Officer Micah Young said on the company's third-quarter earnings call. Pressed there on asset sales, CEO Brian Blaser said management is "looking at every option that supports deleveraging."

## Savings aimed at China's price cuts

Young said the program should start delivering in the fourth quarter and ramp through 2027, with slightly more weight in the second half. He put one-time restructuring charges at about $30 million to $35 million, mostly paid in cash in the fourth quarter of 2026.

Blaser said the savings are incremental to the more than $140 million generated over the last couple of years. Most come first from staffing reductions, and management will look at more indirect-spend cuts over the next several months.

The company is also reorganizing into two businesses: Core Diagnostics (labs, immunohematology and informatics) and Point of Care Diagnostics (the Sophia, Triage and NULEXA lines).

The program responds to China's nationwide pricing guidelines for diagnostic tests, finalized in mid-August. China revenue fell 45% in the quarter as distributors cut inventory. Management expects destocking through 2026 and heavier price pressure in 2027, with China falling from about 8% of revenue this year to about 4% to 5% next year. Young said the savings should more than offset those headwinds.

## Asked about selling Lex or China

A Jefferies analyst asked whether moving the Lex molecular platform into point of care meant no sale was coming. Blaser said he would not "comment on any specific rumors" and called cash flow and deleveraging the highest priorities.

A JPMorgan analyst asked whether divesting China to pay down debt was possible. Blaser said the economics there remain "favorable" even after the changes, and that over the long term management will "look at all different alternatives" to optimize shareholder value.

## Leverage at 4.5 times

Net debt was about $2.8 billion at quarter end, Young said, and net leverage was 4.5 times adjusted EBITDA, up from 4.3 times in the second quarter. The company ended the quarter with $166 million in cash.

It amended its credit agreement to lift the maximum leverage ratio to 5.5 times through the second quarter of 2028, after which the covenant steps down.

Third-quarter revenue was $619 million, down 12% on a constant-currency basis. Point of care revenue fell 27%, including a 39% drop in respiratory, and Blaser said the outlook stays cautious for the rest of the year despite an early start to the season. Free cash flow was about break-even, against negative $95 million a year earlier.

Full-year revenue guidance narrowed to $2.52 billion to $2.54 billion, from $2.52 billion to $2.6 billion, with adjusted EBITDA of $540 million to $545 million.

Young said fourth-quarter free cash flow will absorb most of the restructuring cash cost.

Learn

- [How To Read An Earnings Call Transcript: Start With Guidance, Then Find What's Missing →](https://www.bullished.co/learn/how-to-read-an-earnings-call/)  
How to read an earnings call transcript: check guidance first, look for dropped metrics, compare growth with last quarter, and watch hedged wording.

### More on QuidelOrtho

- [QuidelOrtho Revenue Falls 12% To $619 Million, Trims Outlook And Starts Restructuring](https://www.bullished.co/quidelortho-revenue-falls-12-to-619-million-trims-outlook-and-starts-restructuring-b6232a59/)

[All QuidelOrtho (QDEL) coverage →](https://www.bullished.co/tag/qdel/)